Compare SMX & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | CLGN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Ireland | Israel |
| Employees | 19 | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 18.4M |
| IPO Year | N/A | 2015 |
| Metric | SMX | CLGN |
|---|---|---|
| Price | $8.10 | $0.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 353.2K | 27.7K |
| Earning Date | 04-23-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $0.50 |
| 52 Week High | $490.00 | $4.98 |
| Indicator | SMX | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.47 | 35.28 |
| Support Level | $7.98 | N/A |
| Resistance Level | $8.90 | $0.73 |
| Average True Range (ATR) | 2.39 | 0.09 |
| MACD | -0.26 | 0.02 |
| Stochastic Oscillator | 5.25 | 2.84 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.